vs
MEDICAL PROPERTIES TRUST INC（MPW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
MEDICAL PROPERTIES TRUST INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$270.3M vs $207.3M），MEDICAL PROPERTIES TRUST INC净利率更高（6.5% vs -62.0%，领先68.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 16.6%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -0.2%）
Medical Properties Trust, Inc.（MPT）是一家总部位于美国阿拉巴马州伯明翰的跨国房地产投资信托基金（REIT），主要在美欧地区收购、投资医疗保健设施与营利性医疗控股公司，资产收购多采用售后回租模式，原业主出售资产后成为其租户，租户通常需签署长期三净租赁协议。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
MPW vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.3M | $207.3M |
| 净利润 | $17.6M | $-128.6M |
| 毛利率 | 95.8% | — |
| 营业利润率 | 9.7% | -54.7% |
| 净利率 | 6.5% | -62.0% |
| 营收同比 | 16.6% | 25.9% |
| 净利润同比 | 104.3% | 3.5% |
| 每股收益（稀释后） | $0.03 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $270.3M | $207.3M | ||
| Q3 25 | $237.5M | $159.9M | ||
| Q2 25 | $240.4M | $166.5M | ||
| Q1 25 | $223.8M | $139.3M | ||
| Q4 24 | $231.8M | $164.6M | ||
| Q3 24 | $225.8M | $139.5M | ||
| Q2 24 | $266.6M | $147.0M | ||
| Q1 24 | $271.3M | $108.8M |
| Q4 25 | $17.6M | $-128.6M | ||
| Q3 25 | $-77.7M | $-180.4M | ||
| Q2 25 | $-98.4M | $-115.0M | ||
| Q1 25 | $-118.3M | $-151.1M | ||
| Q4 24 | $-412.3M | $-133.2M | ||
| Q3 24 | $-801.2M | $-133.5M | ||
| Q2 24 | $-320.6M | $-131.6M | ||
| Q1 24 | $-875.6M | $-170.7M |
| Q4 25 | 95.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 91.8% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 96.5% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 84.9% | — |
| Q4 25 | 9.7% | -54.7% | ||
| Q3 25 | -28.0% | -106.9% | ||
| Q2 25 | -36.7% | -64.8% | ||
| Q1 25 | -48.5% | -102.6% | ||
| Q4 24 | -173.7% | -74.3% | ||
| Q3 24 | -350.7% | -94.6% | ||
| Q2 24 | -114.5% | -79.1% | ||
| Q1 24 | -318.6% | -151.9% |
| Q4 25 | 6.5% | -62.0% | ||
| Q3 25 | -32.7% | -112.8% | ||
| Q2 25 | -40.9% | -69.0% | ||
| Q1 25 | -52.8% | -108.5% | ||
| Q4 24 | -177.8% | -80.9% | ||
| Q3 24 | -354.8% | -95.7% | ||
| Q2 24 | -120.3% | -89.5% | ||
| Q1 24 | -322.7% | -156.8% |
| Q4 25 | $0.03 | $-1.28 | ||
| Q3 25 | $-0.13 | $-1.81 | ||
| Q2 25 | $-0.16 | $-1.17 | ||
| Q1 25 | $-0.20 | $-1.57 | ||
| Q4 24 | $-0.68 | $-1.34 | ||
| Q3 24 | $-1.34 | $-1.40 | ||
| Q2 24 | $-0.54 | $-1.52 | ||
| Q1 24 | $-1.46 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $540.9M | $421.0M |
| 总债务越低越好 | $9.7B | — |
| 股东权益账面价值 | $4.6B | $-80.0M |
| 总资产 | $15.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 2.11× | — |
8季度趋势，按日历期对齐
| Q4 25 | $540.9M | $421.0M | ||
| Q3 25 | $396.6M | $202.5M | ||
| Q2 25 | $509.8M | $176.3M | ||
| Q1 25 | $673.5M | $127.1M | ||
| Q4 24 | $332.3M | $174.0M | ||
| Q3 24 | $275.6M | $150.6M | ||
| Q2 24 | $606.5M | $480.7M | ||
| Q1 24 | $224.3M | $112.3M |
| Q4 25 | $9.7B | — | ||
| Q3 25 | $9.6B | — | ||
| Q2 25 | $9.6B | — | ||
| Q1 25 | $9.5B | — | ||
| Q4 24 | $8.8B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.4B | — | ||
| Q1 24 | $10.1B | — |
| Q4 25 | $4.6B | $-80.0M | ||
| Q3 25 | $4.7B | $9.2M | ||
| Q2 25 | $4.8B | $151.3M | ||
| Q1 25 | $4.8B | $144.2M | ||
| Q4 24 | $4.8B | $255.0M | ||
| Q3 24 | $5.4B | $346.8M | ||
| Q2 24 | $6.2B | $432.4M | ||
| Q1 24 | $6.7B | $140.3M |
| Q4 25 | $15.0B | $1.5B | ||
| Q3 25 | $14.9B | $1.2B | ||
| Q2 25 | $15.2B | $1.3B | ||
| Q1 25 | $14.9B | $1.3B | ||
| Q4 24 | $14.3B | $1.5B | ||
| Q3 24 | $15.2B | $1.5B | ||
| Q2 24 | $16.2B | $1.6B | ||
| Q1 24 | $17.3B | $1.3B |
| Q4 25 | 2.11× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | 2.00× | — | ||
| Q1 25 | 1.99× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 1.69× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 1.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $230.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 13.11× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $230.8M | $-99.8M | ||
| Q3 25 | $18.6M | $-91.4M | ||
| Q2 25 | $51.7M | $-108.3M | ||
| Q1 25 | $384.0K | $-166.5M | ||
| Q4 24 | $245.5M | $-79.3M | ||
| Q3 24 | $59.2M | $-67.0M | ||
| Q2 24 | $35.3M | $-77.0M | ||
| Q1 24 | $74.3M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | 13.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MPW
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
